| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2010 | US7705033 Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| 04/27/2010 | US7705032 Method and composition for treating burned skin |
| 04/27/2010 | US7705031 Benzimidazoles useful as modulators of ion channels |
| 04/27/2010 | US7705030 2-Amino-5-[3-(2fluoropyridin-3-yl)phenyl]-3methyl-5-[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]-3,5-dihydro-4H-imidazol-4-one; Alzheimer's disease, cognitive impairment, Down's Syndrome, senile dementia, cerebral amyloid angiopathy, neurofibrillary tangles, beta -amyloid deposits |
| 04/27/2010 | US7705029 Acrylonitrile derivatives for inflammation and immune-related uses |
| 04/27/2010 | US7705028 metabolic syndrome, diabetes, cholestatic liver disease, fibrosis; improved glucose tolerance and decreased insulin resistance; 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1-naphthalenecarboxylic acid |
| 04/27/2010 | US7705026 Biaryl heterocyclic compounds and methods of making and using the same |
| 04/27/2010 | US7705025 Histamine H3 receptor agents, preparation and therapeutic uses |
| 04/27/2010 | US7705024 cannabinoid receptors modulators; metabolic syndrome, obesity, hyperlipidemia, type II diabetes, atherosclerosis, substance addiction, liver cirrhosis, schizophrenia, sexual dysfunction, anxiety; 5-(5-(5-bromoselenophen-2-yl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-3-tert-butyl-1,2,4-oxadiazole |
| 04/27/2010 | US7705023 Indoles useful in the treatment of inflammation |
| 04/27/2010 | US7705022 IDO inhibitors and methods of use thereof |
| 04/27/2010 | US7705021 3-(4-Benzyloxy-3-methoxy-phenyl)-3-methoxy-2-(2-pyridin-2-yl-ethyl)-2,3-dihydro-isoindol-1-one; viricides; anticarcinogenic agents |
| 04/27/2010 | US7705020 Benzimidazolone carboxylic acid derivatives |
| 04/27/2010 | US7705019 Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| 04/27/2010 | US7705018 Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| 04/27/2010 | US7705017 Compounds for treatment of neurodegenerative diseases |
| 04/27/2010 | US7705016 administering small molecule capable of inhibiting CPT1(carnitine palmitoyl transferase1) is 2-tetradecylglydate (TDGA) or (R)-N-(tetradecylcarbamoyl)-aminocarnitine |
| 04/27/2010 | US7705015 Substituted pyrroline kinase inhibitors |
| 04/27/2010 | US7705014 e.g. 2-{4-[(3-hydroxy-4,7-dihydroisoxazolo[5,4-c]pyridin-6(5H)-yl)methyl]phenyl}-3-phenyl-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity; cancer |
| 04/27/2010 | US7705013 Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases |
| 04/27/2010 | US7705012 7-iminomethyl or 7-oxymethyl camptothecin derivatives conjugated, possibly by means of suitable spacers, to cyclopeptide derivatives containing the arginine-glycine-aspartic acid sequence; anticarcinogenic, antimetastasis agent; high affinity for integrin receptors alpha v beta 3 and alpha v beta 5 |
| 04/27/2010 | US7705011 Agent for treatment and prevention of endometriosos and uterine adenomyosis |
| 04/27/2010 | US7705010 Use of minoxidil sulfate as an anti-tumor drug |
| 04/27/2010 | US7705009 4-aminopyrimidine-5-thione derivatives |
| 04/27/2010 | US7705008 Prostaglandin analogs |
| 04/27/2010 | US7705007 Cis-imidazolines |
| 04/27/2010 | US7705006 Anti-cancer cyclopenta[g]quinazoline compounds |
| 04/27/2010 | US7705005 Methyl 2-[4-({[2-[2-(2,3-difluorophenyl)ethyl]-4-oxo-1(4H)-quinazolinyl]acetyl}-{[4'-(trifluoromethyl)-4-biphenylyl]methyl}amino)-1-piperidinyl]-2-methylpropanoate, or a salt thereof; preventing or treating diseases such as atherosclerosis, diabetes, rheumatoid arthritis, stroke, inflammation |
| 04/27/2010 | US7705004 Protein kinase inhibitors |
| 04/27/2010 | US7705003 trans-N-{4-[2-[4-(indan-4-yl)-piperazin-1-yl]-ethyl]-cyclohexyl}-acetamidethe; highest affinity to D3 receptor; no disadvantages of each individual receptor action; antidepressant, anxiolitic agent, cognition activator; psychoses, schizophrenia, drug (alcohol, cocaine and nicotine) abuse, hyperactivity |
| 04/27/2010 | US7705002 Na channel and Ca channel antagonists; potentiation; side effects reduction; pains, epilepsy, neurodegenerative disorders, psychiatric disorders,movement disorders, neuroendocrine disorders etc.; 2-hydroxy-1-[4-[3-(2-hydroxyphenyl)phenyl]piperazin-1-yl]-4-methyl-pentan-1-one; |
| 04/27/2010 | US7705001 Therapeutic substituted gamma lactams |
| 04/27/2010 | US7705000 meloxicam suspended in an aqueous glycerol mixture, cellulose thickening agent, taste modifying agents ( sweeteners) and a buffer system for maintaining pH in a range 2 to 4, free of SiO2; alleviating pain and inflammation in both acute and chronic musculo-skeletal disorders |
| 04/27/2010 | US7704999 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| 04/27/2010 | US7704998 Sulfonyl-derivatives as novel inhibitors or histone deacetylase |
| 04/27/2010 | US7704997 Amino-tetrazole analogues and methods of use |
| 04/27/2010 | US7704996 Compounds and compositions useful as cathepsin S inhibitors |
| 04/27/2010 | US7704995 Protein kinase modulators and methods of use |
| 04/27/2010 | US7704994 1-{6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3- pyridinyl}-2-pyrrolidinone and salts; histamine H3 antagonists; Alzheimer's disease; schizophrena; antiepileptic agents; analgesics; neuropathic pain; Parkinson's disease; attention deficit disorder |
| 04/27/2010 | US7704993 9-Bromo-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine; selective serotonin receptor agonists; obesity, eating disorders, psychiatric disorders, Alzheimer Disease, sexual dysfunction; erectile dysfunction; central nervous system disorders; antidiabetic agents; gastrointestinal disorders |
| 04/27/2010 | US7704992 methyl((1S)-1-(((2S)-2-(5-(9-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepin-3-yl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate; inhibit the function of the non-structural proteins (NS5A) |
| 04/27/2010 | US7704991 Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/27/2010 | US7704990 4-(Piperidinomethylaminosulfonyl),7-(methoxy-)-1,4-benzothiazepineprepared by the reaction of 7-(methoxy-)-1,4-benzothiazepine andpiperidinomethylaminosulfonyl chloride using a basic catalyst; ranodinereceptors that regulate calcium channel functioning in cells; skeletal muscular, cardiac disorders |
| 04/27/2010 | US7704989 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics |
| 04/27/2010 | US7704988 N-[3-(4-{(2S,3R)-2-(-(4-{[(2S, 5S, 3R, 4R, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)perhydro-2H-pyran-2-yl]ethyl-2-yl}phenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-oxoazetidin-1-yl}phenyl)propyl]-N-methylmethanesulfonamide; anticholesterol agent; low density lipoprotein; treating atherosclerosis |
| 04/27/2010 | US7704987 Metal complex based on 1,10-phenanthroline binds to histidine of the N-terminal loop of the peptide in such a way that the N-terminal loop (amino acid residues 1-15) is blocked or destabilised to inhibit the binding copper, zinc and iron compounds -ones of magnesium /calcium; Alzheimer,s disease |
| 04/27/2010 | US7704986 Vitamin D3 analogues for the prevention and treatment of bone disorders |
| 04/27/2010 | US7704985 luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects |
| 04/27/2010 | US7704984 Extended estrogen dosing contraceptive regimen |
| 04/27/2010 | US7704983 Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception |
| 04/27/2010 | US7704982 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and its uses |
| 04/27/2010 | US7704981 To decrease the calcemic effect while retaining the ability to suppress parathyroidhormone; hormone inhibitors; metabolic bone disorders; psoriasis; anticarcinogenic agents; transplant rejection; skin disorders; renal osteodystrophy; osteoporosis; vitamin D-resistant rickets; antiarthritic agents; |
| 04/27/2010 | US7704980 ulcerative colitis and Crohn's disease; 1 alpha -hydroxy-2-methylene-19-nor-homopregnacalciferol or 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 |
| 04/27/2010 | US7704979 Materials and methods for the treatment or prevention of obesity |
| 04/27/2010 | US7704978 Methods for treating neuropsychiatric disorders |
| 04/27/2010 | US7704977 Solid oral dosage form containing an enhancer |
| 04/27/2010 | US7704976 Promoting repair of skin and mucous membrane tissues, the product of the present invention exhibits unique effects for controlling inflammation, damage, infection, and exudation; side effect reduction; topical administration |
| 04/27/2010 | US7704975 Modafinil compound and cyclodextrin mixtures |
| 04/27/2010 | US7704974 Method for the treatment and/or prevention of urinary disorders |
| 04/27/2010 | US7704973 Enhancing efficacy of antibodies bind to a cancer cell expressing CD20, HER2, epidermal growth factor receptor, or ganglioside 2 or 3 by orally administering a beta -glucan derived from barley having a backbone consisting of beta -(1,3) and beta -1,4) glycosidic linkages; low toxicity |
| 04/27/2010 | US7704972 Gemcitabine derivatives nanoparticles |
| 04/27/2010 | US7704971 Uracil reductase inactivators |
| 04/27/2010 | US7704970 DNA vaccination for treatment of autoimmune disease |
| 04/27/2010 | US7704969 Transfection complexes |
| 04/27/2010 | US7704968 treating cancer with antisense oligonucleotide complementary to a region of a nuclear factor- kappa B(NF- kappa B) subunit mRNA, contains phosphate backbone chemically modified; leukemia, fibroblast cancer; inhibiting septic shock; biocompatibility with no side effect |
| 04/27/2010 | US7704965 Methods and materials for treating human papillomavirus infections |
| 04/27/2010 | US7704964 Methods and compounds for the targeting of protein to exosomes |
| 04/27/2010 | US7704961 Miticides and nematocides well-tolerated by livestock and domestic animals; effective against pesticide-resistant pests; protection for plant propagation material |
| 04/27/2010 | US7704960 Administering Erythromycin A having had the cladinose moiety in the 3-position removed by acidolysis to produce an antiinflammatory agent having no antibiotic properties; chronic respiratory system disorders; cytokine suppressive antiinflammatory drugs; antiarthritic agents; antiischemic agents |
| 04/27/2010 | US7704959 decrease the number of acne nodules present in the skin of the individual; side effect reduction; treating skin disorders |
| 04/27/2010 | US7704957 For therapy of AIDS |
| 04/27/2010 | US7704951 administering as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein; suitably applicable to diseases with decrease in motor function |
| 04/27/2010 | US7704948 Stool softener and enteric coated bisacodyl; tablets, capsule; laxative; administering the drug |
| 04/27/2010 | US7704924 Library of compounds comprising pyrrolobenzodiazepine moieties |
| 04/27/2010 | US7704737 culturing with an effective amount of granulocyte-macrophage colony stimulating factor, using brain tissue cells; transplantation; treating multiple sclerosis demyelination |
| 04/27/2010 | US7704542 Vitamin/mineral compositions with DHA |
| 04/27/2010 | US7704530 Antimicrobially treated material and methods of preventing coloring thereof |
| 04/27/2010 | US7704526 Sustained release composition for oral administration of drugs |
| 04/27/2010 | US7704523 Microbial cellulose wound dressing for treating chronic wounds |
| 04/27/2010 | US7704516 Administration be done percutaneously (topically), to avoid the first-pass effect and related liver metabolism of the 4-hydroxy tamoxifen; side effect reduction |
| 04/27/2010 | US7704515 Composition and method to improve quality and yield of meat products |
| 04/27/2010 | US7704502 Combinations of antibodies selective for DR5 and other therapeutic agents |
| 04/27/2010 | CA2665543C Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 04/27/2010 | CA2651665C Process for preparing spray dried formulations of tmc125 |
| 04/27/2010 | CA2574985C Composition comprising theanine |
| 04/27/2010 | CA2574984C Composition comprising theanine |
| 04/27/2010 | CA2563042C 4-2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases |
| 04/27/2010 | CA2557666C Method for inducing cell death with carbonyl scavengers |
| 04/27/2010 | CA2551038C Triazole derivatives as vasopressin antagonists |
| 04/27/2010 | CA2542780C Drug and food or drink for improving hyperglycemia |
| 04/27/2010 | CA2495880C Pyrimidine derivatives and their use as cb2 modulators |
| 04/27/2010 | CA2493667C Vanilloid receptor ligands and their use in treatments |
| 04/27/2010 | CA2486571C Pharmaceutical composition |
| 04/27/2010 | CA2476494C Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
| 04/27/2010 | CA2468479C Podophyllotoxins as antiproliferative agents |
| 04/27/2010 | CA2462939C Novel derivatives of isoquinoline, process for their preparation and pharmaceutical compositions containing them |
| 04/27/2010 | CA2461354C Fondant-based pharmaceutical composition |
| 04/27/2010 | CA2449180C Viral polymerase inhibitors |
| 04/27/2010 | CA2437524C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/27/2010 | CA2435552C A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |